Loading clinical trials...

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer | Clinical Trials | Clareo Health

RECRUITINGPHASE1

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer

NCT07315113•Nuvectis Pharma, Inc.

View on ClinicalTrials.gov

Summary

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Provide written informed consent.
•2. 18 years old or older.
•3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
•4. Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
•5. Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.

Exclusion Criteria

•1. Subject's cancer has a known oncogenic driver alteration other than EGFR.
•2. Known EGFR mutations that cause resistance to osimertinib
•3. Known human epidermal growth factor receptor 2 (HER2) overexpression
•4. Any contraindications to treatment with osimertinib

Locations (3)

Massachusetts General Hospital

Boston, Massachusetts, United States

NEXT Houston

Houston, Texas, United States

NEXT Virginia

Fairfax, Virginia, United States

Key Dates

Start Date

December 18, 2025

Primary Completion Date

December 1, 2026

Completion Date

June 1, 2027

Last Updated

January 2, 2026

Enrollment

ESTIMATED participants

Conditions

EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients

Interventions

NXP900

DRUG

Osimertinib

DRUG

Contacts

Erin Belshaw

CONTACT

12016278129 ebelshaw@nuvectis.com

Shay Shemesh

CONTACT

sshemesh@nuvectis.com

Retrospective Study in a NSCLC M+ p

NCT01795352

EGFR Mutated Non-small Cell Lung Cancer Patients

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 2, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions